|
|
Article: Santarus Partners Technology With TAP In Potential $100M Deal.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Santarus Inc. stands to gain up to $100 million through a licensing agreement announced Tuesday with TAP Pharmaceutical Products Inc. aimed at developing a next-generation therapy for upper gastrointestinal diseases.
Santarus, a private company based in San Diego, already has two products in the clinic based on the technology, which is designed to cover a combination of proton pump inhibitors (PPI) plus antacids. Santarus initially licensed the technology from the University of Missouri in an agreement that extends until mid-2016.
Financial terms of the deal call for TAP, of Lake Forest Ill., to pay Santarus an $8 million ...